Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 12Neoplasms 8Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Ovarian Neoplasms 3Osteosarcoma 3Cholangiocarcinoma 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Drug-Related Side Effects and Adverse Reactions 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Advanced Solid Tumor 2Advanced Gastric Cancer 2Thyroid Neoplasms 1Solid Tumor, Adult 1Sarcoma 1Quality of Life 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

camrelizumab 1apatinib 1Folfox protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Primary Liver Cancer × apatinib × Clear all
NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
157 enrolled 17 charts
Gastrointestinal

Advanced Primary Liver Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡